$NGNE
Neurogene Inc. Stock $ngne

$ngne Overview Financials Valuation SEC Filings Company Website

2014 Q3 Form 10-Q Financial Statement

#000119312514304867 Filed on August 11, 2014

Income Statement

Concept	2014 Q3	2014 Q2	2013 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$990.0K	$1.080M	$370.0K
YoY Change	153.85%	191.89%
% of Gross Profit
Research & Development	$5.323M	$4.551M	$1.247M
YoY Change	75.84%	264.93%
% of Gross Profit
Depreciation & Amortization		$71.94K	$15.59K
YoY Change		361.38%
% of Gross Profit
Operating Expenses	$6.310M	$5.632M	$1.617M
YoY Change	84.66%	248.33%
Operating Profit
YoY Change
Interest Expense	$2.000K	$2.000K	$1.769K
YoY Change	21.73%	13.06%
% of Operating Profit
Other Income/Expense, Net	$26.00K	$208.0K	$805.4K
YoY Change	-41.62%	-74.17%
Pretax Income	-$6.284M	-$5.424M	-$811.5K
YoY Change	86.33%	568.39%
Income Tax	-$222.00
% Of Pretax Income
Net Earnings	-$6.284M	-$5.424M	-$811.5K
YoY Change	86.61%	568.39%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$586.9K	-$507.5K	-$2.700M
COMMON SHARES
Basic Shares Outstanding	10.70M shares	10.68M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q3	2014 Q2	2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$40.00M	$35.90M
YoY Change	151.57%
Cash & Equivalents	$15.87M	$17.90M	$17.59M
Short-Term Investments	$24.10M	$18.00M
Other Short-Term Assets	$300.0K	$400.0K
YoY Change	200.0%
Inventory
Prepaid Expenses	$283.9K	$424.2K
Receivables	$100.0K	$0.00
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$40.36M	$36.34M
YoY Change	152.27%
LONG-TERM ASSETS
Property, Plant & Equipment	$97.58K	$116.9K
YoY Change	-2.42%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$8.100M	$16.50M
YoY Change
Other Assets	$13.86K	$16.77K
YoY Change	-86.14%
Total Long-Term Assets	$8.251M	$16.62M
YoY Change	4025.75%
TOTAL ASSETS
Total Short-Term Assets	$40.36M	$36.34M
Total Long-Term Assets	$8.251M	$16.62M
Total Assets	$48.62M	$52.96M
YoY Change	200.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.600M	$2.800M
YoY Change	318.18%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00
YoY Change
Total Short-Term Liabilities	$4.572M	$2.846M
YoY Change	117.7%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$100.0K	$100.0K
YoY Change	-96.3%
Total Long-Term Liabilities	$100.0K	$100.0K
YoY Change	-96.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.572M	$2.846M
Total Long-Term Liabilities	$100.0K	$100.0K
Total Liabilities	$4.635M	$2.939M
YoY Change	-3.43%
SHAREHOLDERS EQUITY
Retained Earnings	-$81.33M	-$75.04M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$43.98M	$50.02M
YoY Change
Total Liabilities & Shareholders Equity	$48.62M	$52.96M
YoY Change	200.09%

Cashflow Statement

Concept	2014 Q3	2014 Q2	2013 Q2
OPERATING ACTIVITIES
Net Income	-$6.284M	-$5.424M	-$811.5K
YoY Change	86.61%	568.39%
Depreciation, Depletion And Amortization		$71.94K	$15.59K
YoY Change		361.38%
Cash From Operating Activities	-$4.180M	-$2.810M	-$1.440M
YoY Change	140.23%	95.14%
INVESTING ACTIVITIES
Capital Expenditures	-$20.00K	$64.61K	$2.537K
YoY Change		2446.75%
Acquisitions
YoY Change
Other Investing Activities	$2.220M	-$31.76M	$110.0K
YoY Change	11000.0%	-28972.73%
Cash From Investing Activities	$2.210M	-$31.83M	$100.0K
YoY Change	10950.0%	-31930.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-50.00K	-390.0K	-90.00K
YoY Change		333.33%
NET CHANGE
Cash From Operating Activities	-4.180M	-2.810M	-1.440M
Cash From Investing Activities	2.210M	-31.83M	100.0K
Cash From Financing Activities	-50.00K	-390.0K	-90.00K
Net Change In Cash	-2.020M	-35.03M	-1.430M
YoY Change	17.44%	2349.65%
FREE CASH FLOW
Cash From Operating Activities	-$4.180M	-$2.810M	-$1.440M
Capital Expenditures	-$20.00K	$64.61K	$2.537K
Free Cash Flow	-$4.160M	-$2.875M	-$1.443M
YoY Change	139.08%	99.27%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-75040984
CY2014Q2	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	0
CY2014Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10695022	shares
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19017252
CY2014Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	11.00
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52918327
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17589632
CY2014Q2	us-gaap	Minority Interest Ownership Percentage By Parent MinorityInterestOwnershipPercentageByParent	1.00	pure
CY2014Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	19727
CY2014Q2	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	0
CY2014Q2	us-gaap	Long Term Loans From Bank LongTermLoansFromBank	0
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2846116
CY2014Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	93096
CY2014Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	880
CY2014Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2826389
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	50024540
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	52963752
CY2014Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	125064633
CY2014Q2	us-gaap	Line Of Credit LineOfCredit	0
CY2014Q2	us-gaap	Liabilities Liabilities	2939212
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17896110
CY2014Q2	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	34383297
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	116869
CY2014Q2	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	16487173
CY2014Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	4830000	shares
CY2014Q2	us-gaap	Short Term Investments ShortTermInvestments	17989220
CY2014Q2	us-gaap	Cash Cash	2144656
CY2014Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	16765
CY2014Q2	us-gaap	Assets Current AssetsCurrent	36342945
CY2014Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	424240
CY2012Q4	us-gaap	Line Of Credit LineOfCredit	0
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2000539
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	73858722
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	19445
CY2013Q4	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	250000
CY2013Q4	us-gaap	Long Term Loans From Bank LongTermLoansFromBank	2036489
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2620105
CY2013Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	221320
CY2014Q2	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	33375
CY2014Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	15751454
CY2014Q2	us-gaap	Assets Assets	52963752
CY2014Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3043734
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-65693708
CY2013Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	1797412
CY2013Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2350660
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-65693708
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	8560
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15649106
CY2013Q4	us-gaap	Line Of Credit LineOfCredit	2286489
CY2013Q4	us-gaap	Liabilities Liabilities	7484092
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11006392
CY2013Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	1799074
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	75465
CY2013Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	27946
CY2013Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	3714276
CY2013Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	1377438
CY2013Q4	us-gaap	Assets Assets	15649106
CY2013Q4	us-gaap	Short Term Investments ShortTermInvestments	2820600
CY2013Q4	us-gaap	Cash Cash	7292116
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	277290
CY2013Q4	us-gaap	Assets Current AssetsCurrent	15296351
CY2013Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	63975
CY2013Q4	aqxp	Derivative Liabilities Noncurrent Redemption Option DerivativeLiabilitiesNoncurrentRedemptionOption	800206
CY2014Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.052083	pure
CY2014Q1	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	5838726
CY2014Q1	aqxp	Net Proceeds From Issuance Initial Public Offering NetProceedsFromIssuanceInitialPublicOffering	47291274
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.92
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2338187
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0188	pure
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	301745	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-16.37
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.93	pure
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6039706	shares
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	220611
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-7472
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2056
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	13016
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1821769
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	97898
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1821769
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	791923
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	947886
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7233
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4940634
	us-gaap	Net Income Loss NetIncomeLoss	-1821769
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	30377
	us-gaap	Interest Expense InterestExpense	3603
	us-gaap	Operating Expenses OperatingExpenses	2613692
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1820070
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	15589093
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	86437
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	17779350
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	155163
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	147930
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	793622
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	236904
	us-gaap	Proceeds From Repurchase Of Redeemable Preferred Stock ProceedsFromRepurchaseOfRedeemablePreferredStock	17999961
	us-gaap	Share Based Compensation ShareBasedCompensation	128157
	aqxp	Amortization Of Preferred Stock Discount AmortizationOfPreferredStockDiscount	144888
	aqxp	Income Tax Expense On Preferred Stock IncomeTaxExpenseOnPreferredStock	476700
	aqxp	Temporary Equity Accretion To Redemption Value Liquidation Preference TemporaryEquityAccretionToRedemptionValueLiquidationPreference	2555728
	dei	Document Type DocumentType	10-Q
	dei	Entity Registrant Name EntityRegistrantName	AQUINOX PHARMACEUTICALS, INC
	dei	Trading Symbol TradingSymbol	AQXP
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y8M9D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.42
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>1. Nature of operations</b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Aquinox Pharmaceuticals, Inc. and its wholly owned subsidiary, Aquinox Pharmaceuticals (Canada) Inc., (consolidated and combined the “Company”—see Note 2 Basis of presentation) are a clinical stage pharmaceutical company discovering and developing oral drug candidates to treat inflammation and cancer. The Company’s primary focus is the development of anti-inflammatory product candidates targeting SHIP1 which is a key regulator of a cellular signaling pathway in immune cells. Aquinox Pharmaceuticals (USA) Inc. was incorporated on May 31, 2007 in the State of Delaware, United States. On January 27, 2014, Aquinox Pharmaceuticals (USA) Inc. changed its name to Aquinox Pharmaceuticals, Inc. (“Aquinox USA”).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Aquinox Pharmaceuticals (Canada) Inc. (“AQXP Canada”), was originally incorporated under the name of 6175813 Canada Inc. on December 26, 2003 under the Canada Business Corporations Act. In May 2014, after a corporate restructuring, the name was changed to Aquinox Pharmaceuticals (Canada) Inc.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> The Company operates in Vancouver, British Columbia, Canada.</p> </div>
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6608988
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.052083	pure
	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	The Company effected a 1-for-19.2 reverse stock split
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0167	pure
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>(b) Use of estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant areas requiring management estimates are the valuation of stock options and warrants, amortization and depreciation, accrual of expenses, valuation allowance for deferred income taxes, and contingencies. Actual results could differ from those estimates.</p> </div>
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6606091	shares
	dei	Document Period End Date DocumentPeriodEndDate	2014-06-30
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	817022	shares
	dei	Entity Central Index Key EntityCentralIndexKey	0001404644
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.43
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.08	pure
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	928430
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	5201288
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	69074
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	34474541
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-105529
	us-gaap	Line Of Credit Facility Increase Accrued Interest LineOfCreditFacilityIncreaseAccruedInterest	9844
	us-gaap	Repayments Of Debt RepaymentsOfDebt	2600000
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	2609844
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	6293
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	268370
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	5429
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9652437
	us-gaap	Unrealized Gain Loss On Securities UnrealizedGainLossOnSecurities	880
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9651557
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1405706
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9446697
	us-gaap	Net Income Loss NetIncomeLoss	-9652437
	us-gaap	Interest Paid InterestPaid	31719
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	880
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	90176
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Into Level3 FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersIntoLevel3	0
	us-gaap	Interest Expense InterestExpense	456196
	us-gaap	Operating Expenses OperatingExpenses	8246731
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6430734
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	319635
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6889718
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	186356
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	19551
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	45328221
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-31829515
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1815997
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1207273
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	53130000
	us-gaap	Proceeds From Repurchase Of Redeemable Preferred Stock ProceedsFromRepurchaseOfRedeemablePreferredStock	-491
	aqxp	Reversal Of Income Tax Payable On Preferred Stock ReversalOfIncomeTaxPayableOnPreferredStock	1897702
	aqxp	Accretion Of Warrant Discount AccretionOfWarrantDiscount	213511
	aqxp	Amortization Of Preferred Stock Discount AmortizationOfPreferredStockDiscount	1884233
	aqxp	Extinguishment Of Discount On Temporary Equity ExtinguishmentOfDiscountOnTemporaryEquity	800206
	aqxp	Income Tax Expense On Preferred Stock IncomeTaxExpenseOnPreferredStock	100291
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	2714100
	us-gaap	Share Based Compensation ShareBasedCompensation	352476
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	49672
CY2014Q1	aqxp	Number Of Non Employee Directors NumberOfNonEmployeeDirectors	4	Directors
CY2013	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	2500000
CY2013	aqxp	Discount On Issuance Of Warrants DiscountOnIssuanceOfWarrants	226255
CY2013	aqxp	Accretion Of Warrant Discount1 AccretionOfWarrantDiscount1	12744
CY2014Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.10
	aqxp	Share Issuance Expenditures Incurred But Not Yet Paid ShareIssuanceExpendituresIncurredButNotYetPaid	50000
	aqxp	Common Stock Reserved For Issuance Description CommonStockReservedForIssuanceDescription	Additionally, the number of shares of common stock reserved for issuance under the 2014 Plan will automatically increase on January 1 of each year for a period of up to 10 years, beginning on January 1, 2015 and ending on and including January 1, 2024, by 4% of the total number of shares of capital outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the board of directors.
	aqxp	Stock Based Compensation Increase In Common Stock Issuance Percentage StockBasedCompensationIncreaseInCommonStockIssuancePercentage	0.04	pure
	aqxp	Extinguishment Of Remaining Share Issuance Costs Due To Conversion Of Preferred Stock ExtinguishmentOfRemainingShareIssuanceCostsDueToConversionOfPreferredStock	439227
	aqxp	Temporary Equity Accretion To Redemption Value Liquidation Preference TemporaryEquityAccretionToRedemptionValueLiquidationPreference	1132893
	aqxp	Period Shares Reserved For Issuance Will Increase PeriodSharesReservedForIssuanceWillIncrease	P10Y
	aqxp	Fee And Penalty On Bank Loan Repayment FeeAndPenaltyOnBankLoanRepayment	100000
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	175500	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.92
CY2013Q2	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1441566
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2013Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0188	pure
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	301745	shares
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-7.89
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.93	pure
CY2013Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6039706	shares
CY2013Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	87870
CY2013Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-21309
CY2013Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	8424
CY2013Q2	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	12846
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-811502
CY2013Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	68502
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-811502
CY2013Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	805358
CY2013Q2	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	947886
CY2013Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2537
CY2013Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	15592
CY2013Q2	us-gaap	Interest Expense InterestExpense	1769
CY2013Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2382104
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-811502
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.08	pure
CY2014Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	817022	shares
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	1616860
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1247103
CY2013Q2	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1427620
CY2013Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
CY2013Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	42130
CY2013Q2	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-87870
CY2013Q2	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	104353
CY2013Q2	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	101816
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	369757
CY2013Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	199069
CY2013Q2	us-gaap	Share Based Compensation ShareBasedCompensation	73483
CY2013Q2	aqxp	Amortization Of Preferred Stock Discount AmortizationOfPreferredStockDiscount	119450
CY2013Q2	aqxp	Income Tax Expense On Preferred Stock IncomeTaxExpenseOnPreferredStock	130609
CY2013Q2	aqxp	Temporary Equity Accretion To Redemption Value Liquidation Preference TemporaryEquityAccretionToRedemptionValueLiquidationPreference	1397863
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.30
CY2014Q2	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2806820
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2014Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0170	pure
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10675260	shares
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.51
CY2014Q2	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	34474541
CY2014Q2	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	972
CY2014Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	195521
CY2014Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-185335
CY2014Q2	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-33151
CY2014Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5424759
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5423879
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	207634
CY2014Q2	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	14501
CY2014Q2	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	390345
CY2014Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	64611
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5424759
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-5424759
CY2014Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	880
CY2014Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	71938
CY2014Q2	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Into Level3 FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersIntoLevel3	0
CY2014Q2	us-gaap	Interest Expense InterestExpense	2388
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	5632393
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4551220
CY2014Q2	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-35022217
CY2014Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
CY2014Q2	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	186356
CY2014Q2	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-390345
CY2014Q2	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-31825052
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1081173
CY2014Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1941810
CY2014Q2	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	2714100
CY2014Q2	us-gaap	Share Based Compensation ShareBasedCompensation	214822
CY2014Q2	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	46837
CY2014Q2	aqxp	Share Issuance Expenditures Incurred But Not Yet Paid ShareIssuanceExpendituresIncurredButNotYetPaid	50000

Files In Submission

Name	View Source	Status
0001193125-14-304867-index-headers.html	Edgar Link	pending
0001193125-14-304867-index.html	Edgar Link	pending
0001193125-14-304867.txt	Edgar Link	pending
0001193125-14-304867-xbrl.zip	Edgar Link	pending
aqxp-20140630.xml	Edgar Link	completed
aqxp-20140630.xsd	Edgar Link	pending
aqxp-20140630_cal.xml	Edgar Link	unprocessable
aqxp-20140630_def.xml	Edgar Link	unprocessable
aqxp-20140630_lab.xml	Edgar Link	unprocessable
aqxp-20140630_pre.xml	Edgar Link	unprocessable
d755698d10q.htm	Edgar Link	pending
d755698dex311.htm	Edgar Link	pending
d755698dex312.htm	Edgar Link	pending
d755698dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NGNE
Neurogene Inc. Stock $ngne

2014 Q3 Form 10-Q Financial Statement

#000119312514304867 Filed on August 11, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NGNE Neurogene Inc. Stock $ngne

2014 Q3 Form 10-Q Financial Statement

#000119312514304867 Filed on August 11, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NGNE
Neurogene Inc. Stock $ngne